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Abstract Vasoactive intestinal peptide (VIP) is a recognized
growth factor affecting many cell types. We have previously
developed a series of lipophilic VIP analogues containing an
N-terminal covalently attached stearyl moiety. The current
studies identified stearyl-Nle17-VIP and stearyl-Nle17-neuro-
tensin6ÿ11VIP7ÿ28, acting at WM concentrations, as cytotoxic
to human keratinocytes. The core C-terminal active VIP-derived
peptide, stearyl-Lys-Lys-Tyr-Leu-NH2 (St-KKYL-NH2), was
identified as being responsible for the observed cytotoxicity.
Cytotoxicity coincided with marked reduction in intracellular
cyclic GMP and was abolished by co-treatment with the
endonuclease inhibitor, aurine-tricarboxylic acid, suggesting
apoptotic mechanisms. Stearyl-VIP derivatives thus offer lead
compounds for future drug development against hyperprolifera-
tive skin conditions. ß 2000 Federation of European Biochem-
ical Societies. Published by Elsevier Science B.V. All rights
reserved.
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1. Introduction
Vasoactive intestinal peptide (VIP) and pituitary adenylate
cyclase activating peptide (PACAP) are members of a family
of regulatory peptides that include secretin and glucagon [1].
VIP, a basic 28 amino acid peptide, originally isolated from
the gastrointestinal system [2], was identi¢ed as a modulator
of growth, survival and di¡erentiation in many cell systems,
including the brain, the gastrointestinal tract, lung and im-
mune cells, of primary origin and cancerous one [1].
VIP e¡ects have also been documented for skin cells [3].
The epidermis, the outermost skin layer, provides the ¢rst
line of defense against the external environment. The major
cell type in the epidermis is the keratinocyte [4]. Normal hu-
man skin contains a variety of neuropeptides that are either
derived from sensory neurons or from skin cells such as ker-
atinocytes, microvascular endothelial cells or ¢broblasts. In
addition, immune cells, that either constitutively reside in
the skin or in¢ltrate under in£ammatory conditions, have
been reported to produce neuropeptides [5]. VIP was directly
implicated in keratinocyte proliferation [6^8].
Apoptosis is an evolutionary conserved, gene-directed, ac-
tive cell death that follows an orderly pattern of morphologic
and biochemical changes, functioning in developmental re-
modeling, regulation of cell numbers, and defense against
damaged, virus-infected, auto-reactive and transformed cells
[9]. Agents and events that activate the apoptotic pathway
include growth factors, hormones, cytokines, UV and Q irra-
diation, disruption of oxidative pathways and cell matrix in-
teractions [10]. The pathway is conceptually divided into three
mechanistically distinct phases: induction (or initiation), e¡ec-
tor and degradation [11]. The epidermis is a continually re-
newing tissue where homeostasis is maintained by factors that
in£uence the interrelated processes of the keratinocytic life
cycle. Premature, excessive or de¢cient apoptosis have all
been linked to the homeostatic dysregulation characteristic
of skin disorders, such as psoriasis [12].
A lipophilic super-agonist of VIP, stearyl-Nle17-VIP (SNV),
was previously described [13], which contains modi¢cations
intended to confer stability, membranal penetration and in-
creased bioavailability. This analog exhibited a 100-fold po-
tency as compared to VIP [14,15] in promoting neuronal sur-
vival, through a cyclic GMP (cGMP)-associated mechanism
[16]. Another previously described VIP analog is the hybrid
antagonist, neurotensin6ÿ11VIP7ÿ28 (VHA, [17]). VHA proved
to be a potent antagonist of VIP, inhibiting VIP-mediated
cAMP formation and inducing neuronal killing e¡ects in vitro
[18]. VHA also antagonized VIP growth promoting actions on
mouse embryos [19] and inhibited proliferation of a variety of
cancer cell lines [20]. Further modi¢cation of the VHA, on the
basis of enhanced activity of SNV, yielded the stearyl-VIP
hybrid antagonist, stearyl-Nle17-neurotensin6ÿ11VIP7ÿ28
(SNH) [14]. This antagonist proved to be 100-fold more po-
tent in producing neuronal cell death than VHA [14,18], and
more potent in lung cancer growth inhibition [21].
It is desirable to have smaller molecules mimicking the par-
ent peptide activity, while o¡ering applicable bene¢t in better
penetration through biological barriers and reduced possible
enzymatic degradation sites. Structure^function analyses, uti-
lizing VIP fragments, have indicated that for most activities,
the entire sequence of the peptide is required for full biolog-
ical function. VIP2ÿ28 retained a similar biological activity to
the parent peptide [22], while shorter fragments (amino acids
7^28, 15^28, 14^28) exhibited 6 10^1000-fold potency as
0014-5793 / 00 / $20.00 ß 2000 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 0 ) 0 1 6 2 9 - X
*Corresponding author. Fax: (972)-3-640 8541.
E-mail: igozes@post.tau.ac.il
Abbreviations: VIP, vasoactive intestinal peptide; SNV, stearyl-Nle17-
VIP; SNH, stearyl-Nle17-neurotensin6ÿ11VIP7ÿ28 ; St-KKYL-NH2,
stearyl-Lys-Lys-Tyr-Leu-NH2 ; ATA, aurine-tricarboxylic acid; PA-
CAP, pituitary adenylate cyclase activating peptide; VHA, neuro-
tensin6ÿ11VIP7ÿ28 ; LDH, lactate dehydrogenase; GnRH, gonadotro-
pin releasing hormone; CHI, cycloheximide; Pr, propionyl; K-SFM,
keratinocyte serum free medium; EGF, epidermal growth factor;
MEM, minimal Eagle’s essential medium; FCS, fetal calf serum
FEBS 23754 8-6-00
FEBS 23754 FEBS Letters 475 (2000) 71^77
measured for smooth muscle relaxation [23], and lower poten-
cies for other activities [22]. While VIP10ÿ28 antagonized VIP
activities [18,24], a smaller fragment derived from the C-ter-
minal of the VIP peptide (amino acids 20^23), stearyl-Lys-
Lys-Tyr-Leu-NH2 (St-KKYL-NH2), was identi¢ed as the
core active site of VIP, responsible for neuroprotective e¡ects
of VIP/SNV [25].
The focus of the present study was the development and
evaluation of VIP analogs as potential inhibitors of keratino-
cytes’ growth, with emphasis on relevance to possible thera-
peutic applications. More speci¢cally, these include the iden-
ti¢cation of VIP-derived minimal sequences, modi¢ed by N-
terminal addition of a stearyl moiety and an amidated C-ter-
minus, capable of capturing the activity of the full sequence,
as well as characterization of the mechanism involved in cell
death induction.
2. Materials and methods
2.1. Solid phase peptide synthesis
Peptides were prepared by solid phase synthesis using the Fmoc
chemistry as described [13,26]. VIP, PACAP27 [27] and VHA were
puri¢ed by reversed-phase high performance liquid chromatography
(RP-HPLC) on a semipreparative RP-18 Lichrospher, 10 Wm 250U10
mm column (Merck, Darmstadt, Germany), eluted by a linear gra-
dient of aqueous acetonitrile (ACN) in 0.1% TFA: t = 0 min, 0%
ACN; t = 0^5 min, 15% ACN; t = 5^60 min, 52.5% ACN at a £ow
rate of 5 ml/min. SNV, SNH and St-KKYL-NH2 were puri¢ed by a
preparative RP-8 Lichrosorb, 7 Wm 250U25 mm column as above:
t = 0 min, 0% ACN; t = 0^10 min, 37.5% ACN; t = 10^50 min, 75%
ACN at a £ow rate of 10 ml/min. Shorter, more hydrophobic peptides
required a longer ACN = 75% run. The isolated peptides were sub-
jected to analytical RP-HPLC under similar conditions as above (£ow
rate 1 ml/min) to con¢rm their purity and to amino acid analysis to
verify their composition. Mass spectrometry was employed for molec-
ular weight determinations.
2.2. Cell cultures
2.2.1. Neonatal keratinocytes. Primary human neonatal keratino-
cytes were purchased from Clonetics (NHEK #CC-2503, CA, USA)
in their cryopreserved form, and cultivated in keratinocyte serum free
medium (K-SFM, Gibco BRL, Gaithersburg, MD, USA) supple-
mented with 25 Wg/ml bovine pituitary extract (BPE) and 0.1 ng/ml
human recombinant epidermal growth factor (EGF). This medium is
based on MCDB 153 medium, enriched by various hormones (insulin
5 Wg/ml, tri-iodothyronine, transferrin, hydrocortisone 0.5 Wg/ml,
cholera toxin, adenine). Subculturing was achieved under serum free
conditions, using trypsin:EDTA solution (0.025:0.01%), and neutral-
izing by soybean trypsin inhibitor (0.05 mg/ml, Biological Industries,
Beit Haemek, Israel).
2.2.2. HaCaT. Human HaCaT keratinocytes were a kind gift
from Prof. Fusenig [28]. The cells were routinely propagated in min-
imal Eagle’s essential medium, MEM, supplemented with 1% Pen-
Strep-nystatin, 2 mM L-Gln and 10% fetal calf serum (FCS, Biological
Industries, Beit Haemek, Israel) under a humidi¢ed atmosphere with
10% CO2 at 37‡C. Subculturing was achieved by trypsinization with
Versene solution (trypsin:EDTA 0.25:0.02%), and neutralizing by se-
rum containing medium.
2.2.3. HT29. The human colon carcinoma cell line was routinely
propagated in RPMI 1640 supplemented with 1% Pen-Strep-nystatin,
2 mM L-Gln and 10% FCS under a humidi¢ed atmosphere with 10%
CO2 at 37‡C. Subculturing was achieved by trypsinization with Ver-
sene solution and neutralizing by serum containing medium.
2.3. Cell viability assays
2.3.1. Neonatal keratinocytes. For cell proliferation assays, cells
were seeded at 10 000/well in 96 well microtiter plates (Nunc, Ros-
kilde, Denmark), in K-SFM supplemented with BPE and EGF. The
following day, medium was changed to K-SFM without EGF and
BPE (basal medium), in order to achieve a quiescent state. Following
48 h, the medium was replaced by fresh basal medium supplemented
with peptides at the indicated concentrations for an additional 22^
24 h. Cells were used in their third or fourth passage. Cell viability
was monitored by 1.5^3 h incubation with MTS reagent (CellTiter 96
AQueous cell proliferation kit, #G5430, Promega, Madison, WI, USA),
oxidation of which by active mitochondria results in color develop-
ment, at 490 nm.
2.3.2. HaCaT. For cell proliferation assays, cells were seeded at
4000/well in 96 well microtiter plates, in 5% FCS-supplemented
MEM. The following day, cells were starved by changing the medium
to MEM supplemented with 0.1% bovine serum albumin (BSA) for a
48 h period, after which the peptides were added, in fresh medium, at
the speci¢ed concentrations and incubation proceeded for a 22^24 h
period. Cell viability was monitored by 1.5^3 h incubation with the
MTS reagent. Alternatively, for moderate starvation or a non-starva-
tion protocol, cells were seeded in 10% FCS-supplemented MEM, and
peptides were added the following day in fresh 2% or 10% FCS-sup-
plemented medium for a 72 h or a 48 h period, respectively. Cell
viability was monitored by 1.5^3 h incubation with the MTS reagent.
2.3.3. HT29. For cell proliferation assays, cells were seeded at
4000/well into 96 well plates in 10% supplemented RPMI 1640 (Bio-
logical Industries, Beit Haemek, Israel). Medium was changed to 0.1%
BSA-supplemented RPMI the following day, for a 48 h period. Stear-
yl peptides were added, in fresh 0.1% BSA medium for an additional
22^24 h. Cell viability was monitored by addition of the MTS reagent
during the last 3 h of incubation.
2.3.4. Lactate dehydrogenase (LDH) determination. Supernatants
from HaCaT cells exposed to stearyl peptides, with or without 25 WM
aurine-tricarboxylic acid (ATA), the endonuclease inhibitor (Sigma,
St. Louis, MO, USA), were collected, from the same wells used for
MTS determination, and LDH activity evaluated by a LDH cytotox-
icity detection kit (Boehringer-Mannheim, Mannheim, Germany), ac-
cording to the manufacturer’s instructions. The combined LDH ac-
tivity from burst cells treated with 5% Triton X-100 in 50 mM Tris^
HCl, and the LDH values obtained from their respective medium
(prior to Triton treatment), were used to de¢ne 100% LDH activity
(per well). Values obtained from samples were normalized according
to their ratio relative to this 100% value.
2.4. Measurements of intracellular cGMP accumulation
HaCaT cells were seeded, 4U105 per 35 mm dish (Corning, MA,
USA), in 5% FCS-supplemented MEM, as above. On the following
day, cells were starved by changing the medium to MEM supple-
mented with 0.1% BSA for a 48 h period. On the fourth day, the
medium was changed to fresh MEM (without supplements). SNV
was added for a stimulation period of 15 min. Control cultures re-
ceived saline. Following stimulation, the cultures were washed three
times with cold phosphate-bu¡ered saline, and the cyclic nucleotides
extracted by 30 min incubation at 4‡C in 80% ethanol and mechanical
removal of the cells. The resulting suspension was pelleted by centri-
fugation at 2000Ug for 15 min at 4‡C. The supernatants were trans-
ferred to fresh tubes and dried by an Eppendorf concentrator 5301
(Eppendorf, Hamburg, Germany). cGMP content in the samples was
assayed by a cGMP enzyme immunoassay system kit (Amersham,
International Plc., Little Chalfont, Buckinghamshire, UK) according
to the manufacturer’s instructions.
2.5. Statistical analyses
Statistical tests employed ANOVA one way analysis of variance
with all pairwise multiple comparison procedures (Student^New-
man^Keuls method).
3. Results
3.1. Anti-proliferative e¡ects of stearyl modi¢ed VIP-related
peptides on HaCaT cells
The lipophilic VIP antagonist SNH was tested for its anti-
proliferative activity on HaCaT cells following a 24 h incuba-
tion period (Fig. 1). Results indicated that at 10 WM, SNH
produced essentially complete cell killing. In order to estimate
the time dependence of cytotoxic e¡ect manifestation, SNH
was applied for a shorter exposure period. Thus, activity of
SNH was already evident after a 2 h exposure, when only 32%
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of the cells maintained their viability, as compared to control
cultures (not shown).
To test whether the stearyl moiety at the micromolar con-
centrations utilized contributed to the cell killing e¡ect, we
further tested SNV. Additional data (see adjoining manu-
script) indicated that VIP and SNV induced keratinocyte
cell proliferation at picomolar to nanomolar concentrations.
However, SNV at a high concentration (10 WM) proved to be
a cytotoxic agent for the HaCaT line, in£icting not only in-
hibition of cell proliferation, but reduced cell survival (Fig. 1).
Based on these observations, aiming to pinpoint the exact
part of the VIP peptide, accountable for the observed cyto-
toxic activity, several stearyl-modi¢ed peptides, encompassing
fragments derived from the entire VIP peptide, were synthe-
sized and evaluated. Similar to VIP, all stearyl peptides em-
ployed were in their C-terminal amidated form. Some of these
peptides also served as controls, examining the possibility of
non-speci¢c, stearyl-dependent, cytotoxic e¡ect. The various
peptides, with the relevant controls, are summarized in Table
1, according to their location in the VIP peptide. Data in
Table 1 indicate the following: ¢rst, stearic acid by itself
was not cytotoxic to HaCaT cells, nor was its mere addition
to a peptide (such as represented by gonadotropin releasing
hormone, GnRH). Second, the N-terminus of the VIP peptide
was less relevant to e¡ect manifestation. Sequences of the
N-terminal and middle part of the VIP peptide were either
inactive or exhibited markedly reduced activity, while the
C-terminus part of the peptide was its active site, speci¢cally,
the KKYL sequence (Fig. 1, Table 1). Third, non-covalent
mixtures of stearic acid with VIP, Nle17-VIP or VHA were
not cytotoxic, nor was the covalently bound propionyl (Pr)-
KKYL-NH2, i.e. the cytotoxic e¡ect was dependent on cova-
lent linkage of both peptide and stearyl moieties. The results
in Table 1 were obtained with cells incubated in the absence of
serum (in the presence of 0.1% BSA). To assess the e¡ects of
increasing serum concentrations on HaCaT survival, cells
(seeded in 10% serum for 24 h) were further incubated with
the stearyl peptides in the presence of serum (2%, 72 h or 10%,
48 h). Results indicated a gradual diminution of the cytotoxic
e¡ect associated with increasing serum concentrations (25% or
60% survival with SNV, 49% or 100% survival with SNH and
29% or 100% with St-KKYL, respectively).
3.2. Cytotoxic e¡ects on neonatal human keratinocytes and
human colon carcinoma HT29 cell line
Since marked cytotoxic e¡ects of SNV, SNH and St-
KKYL-NH2 were observed with the HaCaT cell line, we ex-
amined whether the e¡ect was maintained with human neo-
natal keratinocytes. As presented in Fig. 2, susceptibility to
Table 1
E¡ects of stearyl peptides on HaCaT cell viability
St-peptide sequence Cell survival (percent of control)
5U1036 M 1035 M 5U1035 M
SNV 54 þ 6 22 þ 4 ND
SNH 60 þ 6 4 þ 1 ND
N-Terminus: St-VIP(1^15) inactive inactive 80 þ 4
St-VIP(1^14) 88 þ 3 86 þ 4 ND
Middle part: St-VIP(8^13) [DNYTRL] inactive inactive ND
St-VIP(8^14) inactive inactive 70 þ 3
St-VIP(15^21) inactive inactive 0
C-Terminus: St-VIP(15^28) inactive 87 þ 3 82 þ 4
St-VIP(15^23)PACAP(24^27) 78 þ 8 22 þ 11 ND
St-VIP(21^25) [KYLNS] 89 þ 3 86 þ 2 ND
St-VIP(20^23) [KKYL] 74 þ 9 36 þ 4 ND
Controls : VIP inactive inactive inactive
PACAP27 inactive inactive ND
VIP hybrid antagonist (VHA) inactive inactive ND
Stearic acid inactive inactive inactive
Stearic acid+VIP inactive inactive inactive
Stearic acid+VIP(Nle17) inactive inactive inactive
Stearic acid+VHA inactive inactive inactive
St-GnRH inactive 82 þ 2 76 þ 3
Pr-KKYL inactive inactive inactive
The e¡ects of stearic acid and stearyl containing VIP-derived or control peptides (all in their C-terminal amidated form) on HaCaT cell viabil-
ity was assessed by MTS. Results are presented as mean þ S.E.M. of 3^6 independent experiments. For experimental details, see Fig. 1. ND,
not determined. Inactive indicates þ 10% of control values (assigned to 100%). St = stearyl; Pr = propionyl.
Fig. 1. Starved HaCaT cellsP viability, as assessed by the metabolic
dye, MTS, in the presence of the indicated concentrations of stearyl
peptides: SNV, SNH and St-KKYL-NH2. Cells (4000/well) were
seeded into 96 well plates in 5% FCS-supplemented MEM. The fol-
lowing day, the medium was switched to 0.1% BSA-supplemented
MEM for a 48 h period. Peptides were then added in fresh 0.1%
BSA-supplemented medium for an additional 24 h. The MTS re-
agent was added during the last 3 h of incubation. Means þ S.E.M.
of four independent experiments are indicated. Control cultures
yielded V0.7 optical density (OD) at 490 nm. *P6 0.05;
**P6 0.005; ***P6 0.0005.
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stearyl-modi¢ed VIP-related peptides was maintained in the
neonatal keratinocytes. Similar results were also obtained with
the colon carcinoma cell line, HT29, cultured under similar
conditions as HaCaT (Fig. 3). All three peptides maintained
their impact, demonstrating similar potency and e⁄cacy in the
two cell lines, HaCaT and HT29. A somewhat di¡erent e⁄-
cacy was evident in the neonatal keratinocytes. In either case,
SNH was the most e⁄cacious analog.
3.3. Mode of cytotoxic e¡ect
Microscopic evaluation revealed a change from the cobble
stone appearance under serum-enriched culture conditions
(Fig. 4A) to cellular elongation and a higher degree of intra-
cellular spacing under serum-deprived conditions (Fig. 4B).
The massive cellular death that has occurred following stearyl
peptides treatment (Fig. 1, Table 1) was evaluated microscopi-
cally (Fig. 4C, SNH, 10 WM and similar results were obtained
for SNV and St-KKYL-NH2). A characterization of the pos-
sible mechanism involved, namely, necrotic, apoptotic or a
combination of the two, was performed. To that end, the
endonuclease inhibitor, ATA, an apoptosis marker commonly
utilized to distinguish between these two types of cell death
[29], was applied, at 25 WM concentration, together with the
cytotoxic peptides. ATA interferes with the ¢nal degradation
phase of the apoptotic process (see Section 1). While ATA
itself did not dramatically change cellular morphology (Fig.
4D), a remarkable restoration in cell viability was observed in
cultures co-treated with SNH and ATA (Fig. 4E).
A quantitative evaluation of the results (MTS) showed that
ATA had some intrinsic cytotoxic e¡ect (32 þ 1.5% cell death).
Thus, the ATA-restored viability value (about 70 þ 5% surviv-
al) in the presence of the stearyl peptides (SNH, SNV and St-
KKYL, 5U1036 M and 1035 M, Table 1), as demonstrated
by MTS, was limited to the level of viability observed in wells
containing ATA only. The LDH activity, an indicator of
membranal integrity, exhibited the exact mirror image of the
MTS measurements (Fig. 5).
The dependency of the process upon new protein synthesis
was further explored. To this end, the inhibitor of protein
synthesis, cycloheximide (CHI, 10 Wg/ml), was added to Ha-
CaT cultures together with the peptide. CHI has a cytotoxic
e¡ect by itself, similar in its magnitude to that observed by
5 WM SNH (Table 2). It is not surprising then that co-treat-
ment of CHI and SNH at this concentration did not result in
improved survival of the cells. Although the percent of surviv-
ing cells is almost ¢ve times larger at the 10 WM SNH+CHI,
as compared to 10 WM SNH alone (P6 0.005), the improve-
ment was only marginal compared to a 100% survival.
3.4. cGMP
Control cultures yielded V150 fmol/dish (100%). At the
cytotoxic doses reported here (e.g. 1035 M), SNV decreased
basal cGMP levels in the cells to 38 þ 1% (P6 0.01).
4. Discussion
Many pathological skin conditions are characterized by hy-
perproliferation of keratinocytes, such as psoriasis, dermato-
ses and skin cancers (squamous cell carcinoma and basal cell
carcinoma). Thus, inhibition of keratinocytes growth would
be highly advantageous as a mean for controlling the symp-
toms of hyperproliferative skin diseases. The present study
demonstrates that several peptides, modi¢ed at their N-termi-
nal by a fatty acid moiety, stearyl, acted as potent cytotoxic
agents. The lack of activity by their non-modi¢ed counter-
parts emphasizes the important role of the stearyl moiety,
and the necessity for the covalently attached fatty and peptide
components. We speculate that while the peptide interacts
with its speci¢c receptor on the keratinocytic membrane, it
assures close proximity of the stearyl moiety, leading to mem-
brane perturbation. Speci¢city of the phenomenon was dem-
onstrated as follows. (1) Stearic acid, by itself, was inactive in
inducing cell death, even at concentrations higher than the
ones required for maximal cytotoxic manifestation. (2) Some
VIP sequences were inactive despite the stearyl attachment.
Fig. 3. Starved HT29 cell viability, as assessed by the metabolic
dye, MTS, in the presence of 10 WM stearyl peptides: SNV, SNH
and St-KKYL-NH2. Cells (4000/well) were seeded into 96 well
plates in 10% FCS-supplemented RPMI. The following day, the me-
dium was switched to 0.1% BSA-supplemented RPMI for a 48 h pe-
riod. Peptides were then added in fresh 0.1% BSA-supplemented
medium for an additional 24 h. The MTS reagent was added during
the last 3 h of incubation. Means þ S.E.M. of two independent ex-
periments are indicated. Control cultures yielded V0.7 OD at
490 nm. P6 0.000001 for the three peptides.
Fig. 2. Starved fourth passage (4‡) human keratinocytes viability, as
assessed by the metabolic dye, MTS, in the presence of the indi-
cated concentrations of stearyl peptides: SNV, SNH, St-KKYL-
NH2 and St-VIP(15^23)PACAP(24^27). Primary neonatal human
keratinocytes that have undergone three trypsinization cycles (i.e.
fourth passage (4‡)) were seeded into 96 well plates (10 000 cells/
well) in complete K-SFM. A day following seeding, the medium
was replaced by basal K-SFM for a 48 h period. Peptides were then
added in fresh basal K-SFM for an additional 24 h. Means þ S.E.M.
of two independent experiments are indicated. Control cultures
yielded V0.5 OD at 490 nm. P6 0.00001 for all data presented
(peptide-treated versus untreated control = 100% viability).
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(3) Short-time exposure to SNH (2 h) resulted in the manifes-
tation of the majority of the cytotoxic e¡ect, a characteristic
of receptor-mediated interaction. Lastly, (4) in the process of
elucidating the minimal VIP sequence, which maintains the
cytotoxic e¡ect, the KKYL sequence was identi¢ed, a se-
quence shared by all the stearyl peptides that turned out to
be active. This ¢nding, together with other observations re-
garding active VIP sequences, further implies that as far as
keratinocytes are concerned, the N-terminus of the peptide is
less relevant to e¡ect manifestation, as evident by the replace-
ment of the ¢rst six amino acids in SNH vs. SNV. Further-
more, while sequences of the N-terminal and middle part of
the VIP peptide were less or not active compared to other
sequences, activity seemed to reside in the C-terminus part
of the VIP peptide, speci¢cally KKYL. Certain amino acids
in combination with this core peptide may enhance/improve
the KKYL sequence cytotoxic activity. A recent publication
from our laboratory [25] has identi¢ed the St-KKYL-NH2 as
the core active site of VIP, with picomolar concentrations
capturing the neurotrophic e¡ects o¡ered by the entire 28
amino acid parent, SNV, in model systems for Alzheimer’s
disease.
Fig. 4. Phase contrast microscopy of HaCaT cultures. Pictures were taken using an Olympus CK2 microscope equipped with an Olympus
SC35 camera. A: Control cultures (10% FCS-supplemented MEM). B: HaCaT cells following a 48 h growth in 0.1% BSA-supplemented MEM
(starved HaCaT). C: Starved HaCaT cells following a 24 h treatment with 10 WM SNH. D: Starved HaCaT cells following a 24 h treatment
with ATA (25 WM). E: Starved HaCaT cells following a 24 h co-treatment with 10 WM SNH and 25 WM ATA. All photographs were taken
under the same conditions.
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Previously, Fermor et al. [30] have reported the cytotoxic
e¡ect of several fatty acids. All human lines, that were exam-
ined, responded in a dose-dependent cell death to the presence
of 10^50 WM stearic acid, with varying sensitivities. While no
clear answer exists to explain the observed cytotoxic e¡ect,
non-speci¢c toxicity as a result of lipid droplets or lipid in-
clusions in the cytoplasm of the cells (steatosis), leading to
irreversible cell degeneration [31], as well as speci¢c e¡ects
on membrane function [32] were speculated. Due to the fact
that previous studies have associated cytotoxicity with stearic
acid, we speci¢cally assessed the possible cytotoxic e¡ects of
the free acid. Although no cytotoxic e¡ect of free stearic acid
was evident in HaCaT cells, a possible contribution of the
fatty moiety to the observed e¡ect should be considered.
However, speci¢city was observed in that St-VIP(1^15) did
not show any cytotoxic e¡ect at 1035 M, while under those
conditions, SNH treatment resulted in 96% cell death and
SNV treatment resulted in 78% death, with their non-lipo-
philic derivatives being totally inactive (Table 1). These results
suggest that a covalent linkage between a certain peptidic
structure and stearic acid is required for the cytotoxic e¡ect.
As this publication [30] was originally based on the assump-
tion that cancerous cells are more susceptible to fatty acids
than normal cells, and the HaCaT line, although not cancer-
ous, may have some characteristics of transformed cells, the
e¡ect of the active stearyl peptides on neonatal keratinocytes
was examined. Whereas the cytotoxic e¡ect was less pro-
nounced, it was maintained in these cells. The e¡ect was
also evident in the human colon carcinoma, HT29. SNV,
SNH and St-KKYL-NH2 all maintained their impact, as
well as similar potency ranking in the three cell types, SNH
being the most e⁄cacious one in starved cells. The less pro-
nounced e¡ect in the case of the neonatal keratinocytes is
attributed to the fact that they are not starved at such harsh
conditions as the HaCaT (as K-SFM contains various growth
factor additives, even when lacking BPE and EGF). It thus
seems that in order to obtain maximal e¡ect manifestation,
the cells must be cultured under extreme conditions. This ob-
servation is further supported by the ¢nding that incubation
of the HaCaT line with the stearyl peptides, but with serum,
resulted in diminution of the e¡ect (especially for SNH), until
its total abolishment. The fact that SNV maintains its cyto-
toxicity even in the presence of serum may indicate a higher
binding a⁄nity to the receptor, or a higher selectivity to a
speci¢c receptor, relative to SNH and St-KKYL-NH2.
Culturing HaCaT cells in serum-deprived conditions re-
sulted in an apparent increase in VIP receptor 1 (VPAC1R)
expression, with no parallel change in VIP receptor 2
(VPAC2R, see adjoining manuscript). Thus, modi¢cation in
receptors’ expression, following starvation, may provide an
additional explanation to the observed variation in the degree
of cytotoxicity (within HaCaT under di¡erent culture condi-
tions and between HaCaT and the neonatal keratinocytes).
Viewed this way, the observation of cytotoxic e¡ect being
dependent on culture conditions may further support the spe-
ci¢city of the cytotoxic peptide phenomenon, as a higher level
of receptors expressed at the cell surface implies a higher level
of stearyl in proximity to interfere at the cell membrane. In
addition, previous publications from our laboratory have
demonstrated that the stearyl-modi¢ed peptides di¡erentiate
between di¡erent VIP receptors [14]. The VIP hybrid antago-
nist (VHA) inhibited VIP-stimulated cAMP formation in as-
troglial cells, while SNH was essentially inactive. In contrast,
SNH was at least 100-fold more potent than VHA in produc-
ing neuronal cell death [14]. Thus, superior activity of SNV
and SNH in the present keratinocyte model may also involve
a parameter of preference to speci¢c VIP receptors on these
cells, and may bear signi¢cance in targeting speci¢c VIP-re-
lated drugs toward therapeutics.
ATA, a triphenylmethane dye, has previously been used to
establish the causal relationship between DNA laddering and
cell death. As such, it was shown to inhibit nuclease activity,
resulting in reduced DNA fragmentation, associated with in-
creased cell survival [33]. However, ATA may have additional
e¡ects, among them are in£uences on receptors to other
growth factors, indicative of a multiple mechanisms of action
[33]. Remarkable restoration in cell viability, obtained by co-
incubation of stearyl peptides and ATA, thus suggests that the
cell death induced by SNV, SNH and St-KKYL-NH2 was
associated with pathways a¡ected by ATA, such as the apop-
totic pathway, or involved in growth regulation by other fac-
tors.
Furthermore, it seems that new protein synthesis is respon-
sible only in part for the suggested apoptotic cell death in this
system. Data in the literature report of many examples where
inhibitors of RNA or protein synthesis fail to interfere with
the apoptotic pathway. On the contrary, some of these inhib-
itors were reported to enhance the susceptibility of cells to
apoptosis induction or even induced apoptosis by themselves,
Fig. 5. Restoration of cell viability by simultaneous incubation of
starved HaCaT with 25 WM ATA and SNV, SNH or St-KKYL-
NH2. Cell viability was evaluated by LDH release. For experimental
details, see legend to Fig. 1. 100% LDH was obtained by combining
intracellular LDH values (5% Triton X-100 extract) and the corre-
sponding conditioned medium values. Means þ S.E.M. of three inde-
pendent experiments are indicated. Signi¢cant di¡erences were ob-
served between cultures+peptide+ATA as compared to cultures+
peptide only: *P6 0.002; **P6 0.0001; ***P6 0.00001.
Table 2
E¡ects of CHI co-treatment on SNH cytotoxicity in HaCaT cells
Treatment Surviving cells (%)
Control 100 þ 2.6
CHI (10 Wg/ml) 69 þ 1.4
SNH (5 WM) 66 þ 3.2
SNH (10 WM) 1.8 þ 0.8
SNH (5 WM)+CHI 64 þ 2.8
SNH (10 WM)+CHI 8.8 þ 1.8
CHI was added simultaneously with SNH on the fourth day of cul-
turing. Data represent percent of surviving cells relative to control.
Results are presented as mean þ S.E.M. of two independent experi-
ments. For experimental details, see Fig. 1.
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thus indicating that macromolecular synthesis is not a general
requirement for apoptosis [34]. For instance, DNA degrading
enzymes were found to be constitutively present in the nucleus
and only require activation.
While cAMP was not implicated in the SNV-induced e¡ects
[14], SNV (femtomolar^nanomolar concentrations)-mediated
increases in cGMP were implicated in neuronal survival [16].
Here, cytotoxic SNV concentrations signi¢cantly reduced
cGMP levels. Hence, reduced cGMP levels may, in combina-
tion with other signals, initiate apoptosis.
Dysregulation of the apoptotic pathway has been impli-
cated in the pathogenesis and promotion of skin diseases,
such as skin cancer and psoriasis. Haake and Polakowska
[11] suggested that terminal di¡erentiation of the keratinocyte
is a specialized form of apoptosis. Apoptosis was suggested as
the default pathway taken in the absence of continued prolif-
eration or normal di¡erentiation. The time between commit-
ment to death and execution of the apoptotic e¡ector phase
was suggested to be extended in normally di¡erentiating ker-
atinocytes, relative to rapid apoptosis of abnormal or un-
necessary keratinocytes, to allow expression of proteins sub-
serving the di¡erentiated function. For normal function, the
apoptotic pathway, as the foundation of keratinocyte terminal
di¡erentiation, must be completed. In psoriasis, failure to
complete the apoptotic pathway may result in abnormal re-
tention of nuclei in the stratum corneum (parakeratosis [11]).
Thus, the cytotoxic e¡ect of the stearyl peptides may be a
result of their induction of excessive di¡erentiation in the
HaCaT keratinocytes, resulting in unavoidable death. Regard-
less of the mechanism underlying cell death induction, the
development of potent skin permeable agents having anti-pro-
liferative e¡ect is highly favorable. The stearyl peptides were
speci¢cally so designed to increase/enable their penetration
through biological barriers, such as the skin. Thus, the ob-
served cytotoxic e¡ect of SNH, SNV and even more so the
maintenance of e¡ect by St-KKYL-NH2 seem to have great
promise in developing therapeutic agents for the topical treat-
ment of hyperproliferative skin disorders.
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